上海交通大学学报（医学版）

上海交通大学学报(医学版) ›› 2020, Vol. 40 ›› Issue (12): 1665-1671.doi: 10.3969/j.issn.1674-8115.2020.12.018

• 综述 • 上一篇    下一篇

受体酪氨酸激酶抑制剂在急性髓系白血病中的临床应用概况

董新怡1，范秋月1，邱树涵1，周嘉瑶1，卢 莹2   

  1. 1.上海交通大学医学院临床医学系，上海200025；2.上海交通大学医学院病理生理学系，上海200025
  • 出版日期:2020-12-28 发布日期:2021-02-02
  • 通讯作者: 卢 莹，电子信箱：stove@shsmu.edu.cn。
  • 作者简介:董新怡（2000—），女，临床医学八年制；电子信箱：1171153410@qq.com。
  • 基金资助:
    国家自然科学基金（81770146,81970131）；上海交通大学医学院第十三期大学生创新训练项目（1319083）。

Clinical application of receptor tyrosine kinase inhibitors to acute myeloid leukemia

DONG Xin-yi1, FAN Qiu-yue1, QIU Shu-han1, ZHOU Jia-yao1, LU Ying2   

  1. 1.Department of Clinical Medicine, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China; 2.Department of Pathophysiology, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
  • Online:2020-12-28 Published:2021-02-02
  • Supported by:
    National Natural Science Foundation of China(81770146, 81970131); The 13th Undergraduate Training Programs for Innovation of Shanghai Jiao Tong University School of Medicine (1319083).

PDF (PC)

333

摘要： 受体酪氨酸激酶（receptor tyrosine kinases，RTKs）控制着细胞的基本活动，包括增殖、周期控制、凋亡、代谢等。相应地，RTKs基因突变导致的异常激活在肿瘤的发生、发展中起重要作用。近年来，针对RTKs研发的受体酪氨酸激酶抑制剂（receptor tyrosine kinase inhibitors，rTKI）研究进展迅速并已在多种类型肿瘤的临床治疗中取得了良好的效果，如慢性粒细胞白血病、非小细胞肺癌和乳腺癌等。急性髓系白血病（acute myeloid leukemia，AML）中， Fms样酪氨酸激酶3（Fms-like tyrosine kinase 3，FLT3)抑制剂的临床应用显著改善了FLT3突变患者的预后，对AML的治疗具有重要意义。文章主要介绍rTKI在AML治疗中的临床应用现状，为AML治疗提供参考。

关键词: 急性髓系白血病, 受体酪氨酸激酶, 受体酪氨酸激酶抑制剂

Abstract:

Receptor tyrosine kinases (RTKs) control the basic activities of cells including proliferation, cell cycle, apoptosis, metabolism and so on. Accordingly, abnormal activation caused by mutations of RTKs plays an important part in the formation and development of tumor. For the past few years, the receptor tyrosine kinase inhibitors (rTKI) developed for RTKs have progressed rapidly and achieved good results in clinical treatment in various tumor types, such as chronic myelogenous leukemia, non-small cell lung cancer, breast cancer and so on. As for acute myeloid leukemia (AML), approval and clinical application of inhibitors against Fms-like tyrosine kinase 3 (FLT3) significantly improve prognosis in patients with FLT3 mutations, which is vital for the treatment of AML. The clinical application of rTKI to AML is summarized in this review, providing a reference for the treatment of AML.

Key words: acute myeloid leukemia (AML), receptor tyrosine kinases (RTKs), receptor tyrosine kinase inhibitors (rTKI)

中图分类号: